Regeneron Pharmaceuticals, Inc.
REGN
$1,012.19
$6.930.69%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 3.44B | 3.03B | 3.22B | 3.22B | 3.09B |
| Total Other Revenue | 104.50M | 116.90M | 212.50M | 138.30M | 69.30M |
| Total Revenue | 3.55B | 3.15B | 3.43B | 3.36B | 3.16B |
| Cost of Revenue | 602.60M | 1.68B | 1.69B | 1.51B | 514.00M |
| Gross Profit | 2.94B | 1.46B | 1.74B | 1.85B | 2.64B |
| SG&A Expenses | 758.80M | 689.00M | 737.70M | 640.50M | 652.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 14.60M | 15.30M | -500.00K | -500.00K | -600.00K |
| Total Operating Expenses | 2.45B | 2.39B | 2.43B | 2.15B | 2.14B |
| Operating Income | 1.09B | 758.50M | 1.00B | 1.21B | 1.02B |
| Income Before Tax | 1.63B | 700.70M | 1.15B | 1.11B | 1.08B |
| Income Tax Expenses | 195.80M | -21.30M | -12.00M | 103.00M | 114.50M |
| Earnings from Continuing Operations | 1.43B | 722.00M | 1.16B | 1.01B | 968.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.43B | 722.00M | 1.16B | 1.01B | 968.40M |
| EBIT | 1.09B | 758.50M | 1.00B | 1.21B | 1.02B |
| EBITDA | 1.21B | 872.60M | 1.12B | 1.32B | 1.12B |
| EPS Basic | 13.25 | 6.70 | 10.88 | 9.48 | 9.05 |
| Normalized Basic EPS | 7.28 | 5.33 | 6.56 | 7.88 | 6.51 |
| EPS Diluted | 12.41 | 6.27 | 10.19 | 8.89 | 8.50 |
| Normalized Diluted EPS | 6.82 | 4.99 | 6.15 | 7.39 | 6.11 |
| Average Basic Shares Outstanding | 108.10M | 107.80M | 106.60M | 106.30M | 107.00M |
| Average Diluted Shares Outstanding | 115.40M | 115.10M | 113.80M | 113.40M | 113.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
